Candidate Gene Polymorphisms Do Not Differ Between Newborns With Stroke and Normal Controls

Steven P. Miller, MD, MAS; Yvonne W. Wu, MD, MPH; Janet Lee, MD; Edward J. Lammer, MD; David M. Iovannisci, MS, PhD; David V. Glidden, PhD; Sonia L. Bonifacio, MD; Abigail Collins, MD; Gary M. Shaw, DrPH; A. James Barkovich, MD; Donna M. Ferriero, MD

Background and Purpose—Neonatal stroke is increasingly recognized with an estimated incidence of one in 4000 live births per year. Pathways involved in the pathophysiology of neonatal stroke are diverse and may include thrombosis and thrombolysis, vascular reactivity, and inflammation.

Methods—We compared frequencies of polymorphisms in genes regulating thrombosis and thrombolysis, nitric oxide, cytokines, vascular tone, and cell adhesion in a hospital-based cohort of 59 newborns with stroke relative to a random sample of 437 California newborns.

Results—Of the 31 polymorphisms evaluated, no variant allele was significantly more common than the reference allele in newborns with stroke than in the general population.

Conclusions—Using a series of polymorphisms in pathways implicated in the etiology of stroke, newborns with stroke were not distinguished from a normal control group. Further studies are needed to determine the interaction of genetic polymorphisms with environmental risk factors in the pathogenesis of neonatal stroke. (Stroke. 2006;37:2678-2683.)

Key Words: brain infarction ■ cerebral infarct ■ cerebral venous thrombosis ■ clinical ■ etiology ■ genetics ■ neonatal ischemia ■ pediatric neurology ■ risk factors ■ sinus thrombosis ■ stroke in children ■ thrombosis ■ young, stroke in

Neonatal stroke is increasingly recognized with an estimated incidence of one in 4000 live births per year. Two types of strokes occur in the newborn period: arterial ischemic and venous thrombotic. The causes of neonatal stroke are likely multifactorial. Disorders predisposing to neonatal stroke include maternal infertility, preeclampsia, prolonged rupture of membranes, and chorioamnionitis as well as neonatal prothrombotic disorders and infection. Yet, many infants with neonatal stroke follow an uncomplicated pregnancy and delivery without identifiable risk factors. Pathways involved in the pathophysiology of neonatal stroke are diverse and may include thrombosis and thrombolysis, vascular reactivity, inflammation, and cell signaling.

The objective of this study was to explore frequencies of polymorphisms in candidate genes regulating thrombosis and thrombolysis, nitric oxide, cytokines, hypertension, and cell adhesion in newborns with stroke relative to randomly selected newborns without stroke from the general population. The candidate genes examined have been associated with the development or progression of cardiovascular disease, including stroke, in adults, but have not all been investigated in the newborn.

Methods

To ascertain cases, we searched the Radiology Information System at our institution for the text strings “infarct,” “thrombosis,” “venous sinus,” and “stroke” among all head magnetic resonance imaging and computed tomography scans performed from 1989 through 2000 in children <18 years of age. Inclusion criteria included (1) a diagnosis of vasoocclusive arterial stroke or sinovenous thrombosis on head magnetic resonance imaging or computed tomography before 1 month of age or (2) presentation after 1 month of age with hemiparesis or seizures and imaging findings of a remote vasoocclusive stroke. Infants presenting after the first month of age with acute stroke were excluded. The imaging features diagnostic of neonatal stroke were confirmed by a neuroradiologist (A.J.B.) who classified the stroke as arterial ischemic or venous thrombotic. Infants were excluded if they were diagnosed with watershed injury alone or a major arterial or venous anomaly (vein of Galen malformation, one patient).

During this period, we identified 71 cases of neonatal stroke of whom 59 had newborn dried blood specimens available for DNA testing. Eligible controls were all deliveries of infants or fetal deaths (>20 weeks gestation) that occurred between January 1987 and 2000.

Received June 6, 2006; accepted August 1, 2006.
From the Departments of Neurology (S.P.M., Y.W.W., J.I., S.L.B., A.C., A.J.B., D.M.F.), Pediatrics (S.P.M., Y.W.W., J.I., S.L.B., A.C., A.J.B., D.M.F.), Epidemiology and Biostatistics (D.V.G.), and Radiology (A.J.B.), University of California, San Francisco, California; the Children’s Hospital Oakland Research Institute (E.J.L., D.M.I.), Oakland, California; the California Birth Defects Monitoring Program (G.M.S.), March of Dimes Birth Defects Foundation, Berkeley, California; and the Department of Pediatrics (Neurology) (S.P.M.), University of British Columbia, Vancouver, BC, Canada.

Correspondence to Steven P. Miller, MD, MAS, Assistant Professor of Pediatrics (Neurology), University of British Columbia, BC Children’s Hospital, Division of Neurology, K-3-180, 4480 Oak St, Vancouver BC V6H 3V4 Canada. E-mail MillerSt@neuropeds.ucsf.edu

© 2006 American Heart Association, Inc.

Stroke is available at http://www.strokeaha.org

DOI: 10.1161/01.STR.0000244810.91105.e9

2678
December 1988 (n=344 214) in selected California counties. A total of 652 infants were randomly selected from this population cohort. These infants had no major structural congenital anomalies identified before the first birthday. Interviews were completed with 488 (75%) mothers. Analyses in the current study were restricted to infants who were live-born because the source of DNA was residual newborn screening blood specimens. Of the 488 infants whose mothers were interviewed, a blood specimen was obtained and genotyped for 437. All interviews and samples were obtained with approval from the State of California Health and Welfare Agency Committee for the Protection of Human Subjects. Genotypes among these infants were tested to verify that their distributions fit Hardy-Weinberg expectations. Only one polymorphism revealed genotype distributions not statistically consistent with Hardy-Weinberg expectations. ADRB2 (Gln27Glu).6

Genomic DNA was isolated from newborn blood specimens as described elsewhere.1 For genotyping, we used a multilocus allelic-specific hybridization assay developed by Roche Molecular Systems (RMS), Alameda, as previously described (some included genes changed from the original description).5,8

The study investigators attempted to contact all identified newborns with stroke; only 26 newborns were located by the study investigators, and of these, 24 were evaluated after voluntary informed consent was obtained. All newborns evaluated at follow up had newborn blood specimens analyzed. The newborns that consented were evaluated using a standard neurologic examination as well as developmental testing by an experienced child psychologist using the Mental Development Index of the Bayley Scales of Infant Development II for children less than 4 years of age and the Wechsler Preschool and Primary Scale of Intelligence for children 4 years of age and older. Neurodevelopmental outcome was classified as abnormal if there were functional motor deficits or the cognitive score was 2 SDs below the mean. Because most newborns could not be contacted, the genotyping was performed without a link to the newborn’s identifying information or clinical condition. The protocol was approved by the Committee on Human Research at the University of California San Francisco and the Department of Health Services, State of California.

In this exploratory analysis, the risk of neonatal stroke for each single nucleotide polymorphism was assessed by calculating odds ratios with 95% confidence intervals. A “recessive” model (homozygous variant compared with heterozygous variant and homozygous wild-type) was used for all single nucleotide polymorphisms, except for F2, F5, and PAI1 G5, which were compared using a “dominant” model (homozygous or heterozygous variant compared with homozygous wild-type).6 Probability values were calculated using χ² test or Fisher exact test (if the number of cases in an individual cell was less than 5) and are presented without adjustment for multiple comparisons. The number of at-risk genotypes in cases and controls was compared using the nonparametric Mann–Whitney U test. Using Classification and Regression Tree (CART) analysis (R: A Language and Environment for Statistical Computing),10 we explored whether combinations of genetic polymorphisms distinguished newborns with stroke from controls.

Results

Of the 59 infants with neonatal stroke, 35 had arterial ischemic stroke and 24 had venous thrombotic stroke. Of 31 polymorphisms tested, the median number of homozygous variant genotypes in an individual infant with stroke was 2 (range, 0–7), whereas the median number of heterozygous genotypes was 14 (range, 8–19). The distribution of alleles was remarkably similar in cases of stroke and population-based controls (Table). Although an elevated odds ratio (>1.5) was observed for the heterozygous F2 20210 (GA) and F5 Arg506Gln (GA) genotypes, as well as the homozygous SELE Leu554Phe (TT) genotype, the number of cases was small (all \( P>0.1 \)). The median number of at-risk genotypes in an individual infant with stroke was 3 (range, 1–7) and was also 3 (range, 1–9) in controls (\( P=0.6 \)). The median number of prothrombotic alleles in an individual infant with stroke was one (range, 0–3) and was also one (range, 0–4) in controls (\( P=0.1 \)). Furthermore, CART analysis failed to identify any combinations of genotypes that could significantly distinguish cases from controls.

Comparing newborns with arterial and venous strokes, 6 at-risk genotypes were seen with a \( \geq 5\% \) increased frequency in arterial strokes (F2 [20210], FGB [-455], LTA [Thr26Asn], TNF [-308], ADRB2 [Gln27Glu], and SCNN1A [Ala663Thr]), whereas 2 were more common in venous strokes (AGTR1 [1166], ITGB3 [Leu33Pro]) (all \( P<0.07 \)). None of these variant genotypes were significantly more common in newborns with arterial or venous strokes relative to controls.

The median age at follow up was 5.2 years (range, 1–18 years). Neurodevelopmental outcome was abnormal in 11 children (46%): 10 children had functional motor deficits (hemiparesis in nine) and 6 children had abnormal cognitive outcomes. Only one child had abnormal cognitive outcome in the absence of functional motor deficits (unilateral tone/reflex changes only). In an exploratory analysis, the median number of homozygous variant alleles was similar in newborns with abnormal (3 variants) and normal (2 variants) outcomes (\( P=0.2 \)). Similarly, the median number of heterozygous alleles was similar in newborns with abnormal (14 variants) and normal outcomes (14 variants) (\( P=0.3 \)). The limited sample size precluded testing the effect of individual polymorphisms. None of the newborns with follow-up data had an abnormal factor V genotype.

Discussion

In this exploratory study, we found that the frequencies of polymorphisms in candidate genes regulating thrombosis and thrombolysis, nitric oxide synthesis, cytokines, hypertension, and extracellular matrix and cell adhesion pathways were remarkably similar in a hospital-based cohort of newborns with stroke relative to the general California population. In fact, none of the 31 variants evaluated, alone or in combination, was significantly more common in newborns with stroke than in the general population. Our study was limited by a relatively small sample size and a large number of polymorphisms tested. Our study was also limited by the lack of epidemiologic data necessary to study potential interactions between polymorphisms and environmental exposures.

Prothrombotic conditions have been previously implicated in the pathogenesis of neonatal stroke. In the largest series of prothrombotic risk factors in American children with stroke, 63% of children had at least one prothrombotic risk factor and 28% had at least 2 risk factors.11 Although several prothrombotic risk factors were observed, PAI1 homozygosity was the most common abnormality seen in 15 of 56 children.11 In a multicenter case–control study of term newborns with symptomatic ischemic stroke, 62 of 91 patients with stroke (68%) had at least one prothrombotic risk factor compared with 44 control subjects (24%): factor V Arg506Gln mutations, protein C type I deficiency, and elevated lipoprotein (a) levels were found more frequently in cases than controls, whereas
<table>
<thead>
<tr>
<th>Nitric Oxide Polymorphism</th>
<th>Genotype</th>
<th>Neonatal Stroke (59 cases) N (%)</th>
<th>Arterial (35 cases) N (%)</th>
<th>Venous (24 cases) N (%)</th>
<th>General Population (437 controls) N (%)</th>
<th>Odds Ratio*</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOS3 g.(-690)C&gt;T</td>
<td>CC</td>
<td>53 (89.8)</td>
<td>29 (83)</td>
<td>24 (100)</td>
<td>389 (89.6)</td>
<td>0</td>
<td>(0–14.3)</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td></td>
<td>CT</td>
<td>6 (10.2)</td>
<td>6 (17)</td>
<td>0</td>
<td>43 (9.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>0</td>
<td>0</td>
<td>2 (0.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOS3 g.(-922)A&gt;G</td>
<td>AA</td>
<td>36 (61.0)</td>
<td>18 (51)</td>
<td>18 (75)</td>
<td>208 (47.9)</td>
<td>0.4</td>
<td>(0.04–1.5)</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>AG</td>
<td>21 (35.6)</td>
<td>15 (43)</td>
<td>6 (25)</td>
<td>188 (43.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>2 (3.4)</td>
<td>2 (6)</td>
<td>0</td>
<td>38 (8.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NOS3 p.Glu298Asp (G&gt;T)</td>
<td>GG</td>
<td>38 (64.4)</td>
<td>23 (66)</td>
<td>15 (63)</td>
<td>241 (55.5)</td>
<td>0.7</td>
<td>(0.1–2.3)</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>GT</td>
<td>18 (30.5)</td>
<td>9 (26)</td>
<td>9 (37)</td>
<td>161 (37.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs1799983</td>
<td>TT</td>
<td>3 (5.1)</td>
<td>3 (8)</td>
<td>0</td>
<td>32 (7.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombosis/thrombolysis</td>
<td>F2</td>
<td>g.-20210G&gt;A</td>
<td>GG</td>
<td>55 (94.8)</td>
<td>32 (94)</td>
<td>23 (96)</td>
<td>412 (98.1)</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>rs1799963</td>
<td>GA</td>
<td>3 (5.2)</td>
<td>2 (6)</td>
<td>1 (4)</td>
<td>8 (1.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F5 p.Arg506Gln (G&gt;A)</td>
<td>GG</td>
<td>56 (94.9)</td>
<td>34 (97)</td>
<td>22 (92)</td>
<td>419 (86.8)</td>
<td>1.6</td>
<td>(0.3–6.0)</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>3 (5.1)</td>
<td>1 (3)</td>
<td>2 (8)</td>
<td>14 (3.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs6025</td>
<td>AA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F7 g.(-323) 10-bp del&gt;ins</td>
<td>del del</td>
<td>39 (66.1)</td>
<td>24 (69)</td>
<td>15 (63)</td>
<td>327 (75.3)</td>
<td>0</td>
<td>(0–3.5)</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>del ins</td>
<td>20 (33.9)</td>
<td>11 (31)</td>
<td>9 (37)</td>
<td>99 (22.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs5742910</td>
<td>ins ins</td>
<td>0</td>
<td>8 (1.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F7 p.Arg353Gln (G&gt;A)</td>
<td>GG</td>
<td>40 (67.8)</td>
<td>25 (71)</td>
<td>15 (63)</td>
<td>344 (79.8)</td>
<td>0</td>
<td>(0–4.0)</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>19 (32.2)</td>
<td>10 (29)</td>
<td>9 (37)</td>
<td>80 (18.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs6046</td>
<td>AA</td>
<td>0</td>
<td>0</td>
<td>7 (1.6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGB g.(-455)G&gt;A</td>
<td>GG</td>
<td>38 (64.4)</td>
<td>18 (51)</td>
<td>20 (83)</td>
<td>277 (64.1)</td>
<td>1.2</td>
<td>(0.33.8)</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>17 (28.8)</td>
<td>13 (37)</td>
<td>4 (17)</td>
<td>131 (30.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>4 (6.8)</td>
<td>4 (12)</td>
<td>0</td>
<td>24 (5.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAI1 g.-675)G5&gt;G4</td>
<td>G5 G5</td>
<td>14 (23.7)</td>
<td>10 (29)</td>
<td>4 (17)</td>
<td>119 (27.5)</td>
<td>1.2</td>
<td>(0.6–2.5)</td>
<td>0.6</td>
</tr>
<tr>
<td></td>
<td>G5 G4</td>
<td>33 (55.9)</td>
<td>18 (51)</td>
<td>15 (62)</td>
<td>216 (49.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>G4 G4</td>
<td>12 (20.3)</td>
<td>7 (20)</td>
<td>5 (21)</td>
<td>98 (22.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAI1 g.0.11053G&gt;T</td>
<td>GG</td>
<td>12 (20.3)</td>
<td>9 (26)</td>
<td>3 (12)</td>
<td>68 (15.8)</td>
<td>1.1</td>
<td>(0.6–2.0)</td>
<td>0.9</td>
</tr>
<tr>
<td>rs7242</td>
<td>GT</td>
<td>25 (42.4)</td>
<td>13 (37)</td>
<td>12 (50)</td>
<td>209 (48.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TT</td>
<td>22 (37.3)</td>
<td>13 (37)</td>
<td>9 (38)</td>
<td>153 (35.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokines</td>
<td>LTA</td>
<td>p.Thr26Asn (C&gt;A)</td>
<td>CC</td>
<td>27 (45.8)</td>
<td>17 (49)</td>
<td>10 (42)</td>
<td>179 (41.2)</td>
<td>1.2</td>
</tr>
<tr>
<td></td>
<td>CA</td>
<td>24 (40.7)</td>
<td>11 (31)</td>
<td>13 (54)</td>
<td>205 (47.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>8 (13.6)</td>
<td>7 (20)</td>
<td>1 (4)</td>
<td>50 (11.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF g.(-376)A&gt;G</td>
<td>AA</td>
<td>56 (94.9)</td>
<td>33 (94)</td>
<td>23 (96)</td>
<td>423 (87.5)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>AG</td>
<td>3 (5.1)</td>
<td>2 (6)</td>
<td>1 (4)</td>
<td>11 (2.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF g.(-308)A&gt;G</td>
<td>AA</td>
<td>48 (81.4)</td>
<td>29 (83)</td>
<td>19 (79)</td>
<td>318 (73.3)</td>
<td>2.1</td>
<td>(0.211.6)</td>
<td>0.3</td>
</tr>
<tr>
<td></td>
<td>AG</td>
<td>9 (15.3)</td>
<td>4 (11)</td>
<td>5 (21)</td>
<td>109 (25.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GG</td>
<td>2 (3.4)</td>
<td>2 (6)</td>
<td>0</td>
<td>7 (1.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF g.(-238)G&gt;A</td>
<td>GG</td>
<td>55 (94.8)</td>
<td>32 (94)</td>
<td>23 (96)</td>
<td>393 (80.6)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>GA</td>
<td>3 (5.2)</td>
<td>2 (6)</td>
<td>1 (4)</td>
<td>41 (9.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Nitric Oxide Polymorphism Genotype | Neonatal Stroke (59 cases) N (%) | Arterial Stroke (35 cases) N (%) | Venous Stroke (24 cases) N (%) | General Population (437 controls) N (%) | Odds Ratio* | 95% CI | P
---|---|---|---|---|---|---|---
**Hypertension and others**

### ADD1
- **p.Gly460Trp** (G>T)
  - **GG** 36 (63.2) 21 (62) 15 (63) 276 (63.6) 0.9 (0.1–4.2) >0.9
  - **GT** 19 (33.3) 11 (32) 8 (33) 142 (32.7)
  - **TT** 2 (3.5) 2 (6) 0 16 (3.7)
- **rs4961**
  - **GG** 36 (63.2) 21 (62) 15 (63) 276 (63.6) 0.9 (0.1–4.2) >0.9
  - **GT** 19 (33.3) 11 (32) 8 (33) 142 (32.7)
  - **TT** 2 (3.5) 2 (6) 0 16 (3.7)

### ADRB2
- **p.Arg16Gly** (A>G)
  - **AA** 7 (11.9) 5 (15) 2 (8) 71 (16.4) 1.0 (0.5–1.9) >0.9
  - **AG** 31 (52.5) 18 (51) 13 (54) 210 (48.5)
  - **GG** 2 (3.5) 2 (6) 0 16 (3.7)
- **rs1042714**
  - **GG** 3 (5.1) 3 (9) 0 58 (13.4)
  - **AG** 31 (52.5) 18 (51) 13 (54) 210 (48.5)
  - **GG** 2 (3.5) 2 (6) 0 16 (3.7)

### AGTR1
- **g.0.1166A>C**
  - **AA** 32 (54.2) 21 (60) 11 (46) 221 (50.3) 0.9 (0.2–2.8) >0.9
  - **AC** 23 (39.0) 13 (37) 10 (42) 186 (42.4)
  - **CC** 4 (6.8) 1 (3) 3 (12) 32 (7.3)
- **rs5186**
  - **AA** 32 (54.2) 21 (60) 11 (46) 221 (50.3) 0.9 (0.2–2.8) >0.9
  - **AC** 23 (39.0) 13 (37) 10 (42) 186 (42.4)
  - **CC** 4 (6.8) 1 (3) 3 (12) 32 (7.3)

### GNB3
- **c.0.825C>T**
  - **CC** 28 (47.5) 14 (40) 14 (58) 185 (42.6) 0.8 (0.3–1.9) 0.7
  - **CT** 25 (42.4) 18 (51) 7 (29) 194 (44.7)
  - **TT** 4 (6.8) 1 (3) 3 (12) 32 (7.3)

### ICAM1
- **p.Gly241Arg** (G>A)
  - **GG** 43 (72.9) 25 (71) 18 (75) 337 (77.6) 0 (0–4.0) >0.9
  - **GA** 16 (27.1) 10 (29) 6 (25) 90 (20.7)
  - **AA** 3 (5.1) 3 (9) 0 58 (13.4)

### ITGA2
- **c.0.873G>A**
  - **GG** 9 (15.3) 6 (17) 3 (13) 165 (38.0) 0.7 (0.2–1.7) 0.5
  - **GA** 44 (74.6) 25 (71) 19 (79) 208 (47.9)
  - **AA** 6 (10.2) 4 (12) 2 (8) 61 (14.1)

### ITGB3
- **p.Leu33Pro** (T>C)
  - **TT** 47 (79.7) 31 (89) 16 (67) 332 (76.5) 1.3 (0.1–6.4) 0.7
  - **TC** 10 (16.9) 4 (11) 6 (25) 91 (21.0)
  - **CC** 2 (3.4) 0 2 (8) 11 (2.5)

### MMP3
- **g.(-1171)A5>A6**
  - **A5 A5** 10 (17.2) 4 (12) 6 (25) 79 (18.3) 1.4 (0.7–2.5) 0.3
  - **A5 A6** 25 (43.1) 16 (47) 9 (38) 212 (49.2)
  - **A6 A6** 23 (39.7) 14 (41) 9 (37) 140 (32.5)

### MTHFR
- **c.0.677C>T**
  - **CC** 25 (42.4) 14 (40) 11 (46) 180 (41.5) 1 (0.4–2.3) >0.9
  - **CT** 27 (45.8) 17 (49) 10 (42) 202 (46.5)
  - **TT** 3 (5.1) 2 (6) 0 16 (3.7)

### NPPA
- **c.0.664G>A**
  - **GG** 53 (89.8) 31 (89) 22 (92) 382 (88.0) 0 >0.9
  - **GA** 6 (10.2) 4 (11) 2 (8) 51 (11.8)
  - **AA** 0 0 0 0

### NPPA
- **c.0.2238T>C**
  - **TT** 48 (81.4) 31 (89) 17 (71) 317 (73.0) 0 (0–5.7) >0.9
  - **TC** 11 (18.6) 4 (11) 7 (29) 112 (25.8)
  - **CC** 0 0 0 0

### SCNN1A
- **p.Trp493Arg** (T>C)
  - **TT** 56 (94.9) 34 (97) 22 (92) 415 (95.6) — —
  - **TC** 3 (5.1) 1 (3) 2 (8) 19 (4.4)

(Continued)
prothrombin and methylenetetrahydrofolate reductase mutations were not significantly different between the groups. In another cohort of 24 newborns with perinatal cerebral infarction confirmed by neonatal magnetic resonance imaging, 10 newborns (42%) had at least one prothrombotic state, including heterozygosity for factor V Leiden in 5 and high factor VIIIc concentrations in 6. Because our cohort was studied exclusively with the multitlocus allele-specific hybridization assay, we could not address abnormalities in protein C type I, lipoprotein (a), or factor VIIIc concentrations. Prothrombotic states have been associated with adverse neurodevelopmental outcome after neonatal stroke in a series of 24 infants: factor V Leiden or raised factor VIIIc were seen in 8 of 11 patients with hemiplegia or global developmental delay, but only one of 13 infants with normal outcome had a prothrombotic risk. Although all 5 infants with hemiplegia in this previous series had factor V Leiden, none of the newborns followed in our study had an abnormality of factor V. Although losses to follow up in our cohort may have resulted in a bias limiting the difference in genotypes between those with and without adverse outcomes, the rates of neurodevelopmental abnormality, including hemiparesis in this cohort, are comparable with other studies. In the present study, the finding that variations in genes regulating thrombosis and thrombolysis were equally common in newborns with stroke and controls may reflect the polymorphisms tested and more representative comparisons that can be generated when a study can use population-based controls.

Summary
The lack of associations in this study highlights the importance of using appropriate control groups when studying the contribution of genetic polymorphisms to the etiology of neonatal stroke. With recent data highlighting the interaction of multiple maternal and infant risk factors in newborns with stroke, further studies are needed to determine the interaction of genetic polymorphisms with environmental risk factors in the pathogenesis of neonatal stroke.

Acknowledgments
The authors thank Rita J. Jeremy, PhD, and Marion Koester, MD, for their expertise and for their support of this study. The authors also acknowledge Dr Suzanne Cheng (Roche Molecular Systems), who contributed materials for the genotyping assay and consulted on interpretation of genotypes.

Sources of Funding
This study was carried out in part in the Pediatric Clinical Research Center, University of California, San Francisco, with funds provided by the National Center for Research Resources, 5 M01 RR-01271, US Public Health Service (D.M.F., Y.W.W., S.P.M.). This study was also funded in part by the Neurological Sciences Academic Development Award grant 5 K12 NS01692 to Y.W.W. and the Canadian Institutes of Health Research Clinician Scientist Program (phase 1) to S.P.M.

Disclosures
Roche Molecular Systems (RMS) provided some reagents that were used to perform the genotyping assays. RMS provided no other support, no role in the design, or conduct of the study; they did provide support for interpreting genotypes but not in the data analysis. RMS did review the manuscript before submission.

References

<table>
<thead>
<tr>
<th>Nitric Oxide</th>
<th>Polymorphism</th>
<th>Genotype</th>
<th>Neonatal Stroke (59 cases) N (%)</th>
<th>Arterial Stroke (35 cases) N (%)</th>
<th>Venous Stroke (24 cases) N (%)</th>
<th>General Population (437 controls) N (%)</th>
<th>Odds Ratio*</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCNN1A</td>
<td>p.Ala663Thr</td>
<td>GG</td>
<td>39 (66.1)</td>
<td>19 (54)</td>
<td>20 (83)</td>
<td>202 (46.5)</td>
<td>0.8</td>
<td>0.2–2.0</td>
<td>0.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(G-&gt;A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2228576</td>
<td>AA</td>
<td>5 (8.5)</td>
<td>5 (14)</td>
<td>0</td>
<td>47 (10.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SELE</td>
<td>p.Ser128Arg</td>
<td>AA</td>
<td>49 (83.1)</td>
<td>28 (80)</td>
<td>21 (88)</td>
<td>356 (82.0)</td>
<td>0.9</td>
<td>0.02–7.1</td>
<td>&gt;0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AC</td>
<td>9 (15.3)</td>
<td>6 (17)</td>
<td>3 (12)</td>
<td>70 (16.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs5361</td>
<td>CC</td>
<td>1 (1.7)</td>
<td>1 (3)</td>
<td>0</td>
<td>8 (1.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SELE</td>
<td>p.Leu554Phe</td>
<td>CC</td>
<td>54 (91.5)</td>
<td>34 (97)</td>
<td>20 (83)</td>
<td>404 (93.1)</td>
<td>7.5</td>
<td>0.09–587.2</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CT</td>
<td>4 (6.8)</td>
<td>1 (3)</td>
<td>3 (13)</td>
<td>29 (6.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs5355</td>
<td>TT</td>
<td>1 (1.7)</td>
<td>0</td>
<td>1 (4)</td>
<td>1 (0.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Odds ratios refers to the homozygous variant for neonatal stroke, except for F2, F5, and PAI1 G5, in which homozygous and heterozygous variants are compared with "wild-type" The P values correspond to the odds ratio calculation.

NOS3 indicates endothelial nitric oxide synthase; F2, factor II prothrombin; F5, factor V; F7, factor VII promoter; F8G, fibrinogen; PAI1 promoter, plasminogen activator inhibitor 1; LTA, tumor necrosis factor beta (lymphotoxin alpha); TNF, tumor necrosis factor; ADD1, alpha adducin; ADRB2, beta 2 adrenergic receptor; AGT, angiotensin 1; AGTR1, angiotensin receptor type I; GNB3, guanine nucleotide-binding protein beta 3 subunit; ITGA1, intracellular adhesion molecule 1; ITGAV, integrin alpha IIb; MMP3, matrix metalloproteinase; MTHFR, methylenetetrahydrofolate reductase; NPPA, natriuretic peptide precursor A; SCNN1A, epithelial sodium channel alpha subunit; SELE, endothelial leukocyte adhesion molecule.


Candidate Gene Polymorphisms Do Not Differ Between Newborns With Stroke and Normal Controls


Stroke. 2006;37:2678-2683; originally published online September 28, 2006;
doi: 10.1161/01.STR.0000244810.91105.c9

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/37/11/2678